Market revenue in 2023 | USD 162.4 million |
Market revenue in 2030 | USD 699.2 million |
Growth rate | 23.2% (CAGR from 2023 to 2030) |
Largest segment | Autologous therapies |
Fastest growing segment | Allogeneic Therapies |
Historical data | 2018 - 2022 |
Base year | 2023 |
Forecast period | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Allogeneic Therapies, Autologous Therapies |
Key market players worldwide | Novartis AG ADR, Gilead Sciences Inc, Bristol-Myers Squibb Co, Johnson & Johnson, JCR Pharmaceuticals Co Ltd, JW (Cayman) Therapeutics Co Ltd Ordinary Shares, Atara Biotherapeutics Inc, Medipost, Beiersdorf AG, Nkarta Inc Ordinary Shares |
Key Regions: U.S. , UK , Canada , Germany , Switzerland
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to cell therapy market will help companies and investors design strategic landscapes.
Autologous therapies was the largest segment with a revenue share of 83.19% in 2023. Horizon Databook has segmented the Japan cell therapy market based on allogeneic therapies, autologous therapies covering the revenue growth of each sub-segment from 2018 to 2030.
The cell therapy market in Japan is driven by several initiatives undertaken by Japanese companies to increase access to cell therapies, coupled with the rising approvals & clinical trials for cell-based therapies, in the country.
For instance, in February 2023, Novo Nordisk A/S and Heartseed, Inc. achieved a significant milestone by administering the first dose to a patient in the phase 1/2 clinical study, known as the LAPiS Study, for HS-001 an investigational cell therapy targeting heart failure.
The clinical phase 1/2 of the LAPiS Study would enroll 10 individuals with advanced heart failure caused by an ischemic heart condition. Thus, such clinical studies & trials for various cell therapies targeting numerous conditions like cardiovascular disease and cancer are expected to boost the competition in the Japan cell therapy market.
Horizon Databook provides a detailed overview of country-level data and insights on the Japan cell therapy market , including forecasts for subscribers. This country databook contains high-level insights into Japan cell therapy market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account